Zhejiang Changming Pharmaceutical

Zhejiang Changming Pharmaceutical is a prominent Chinese pharmaceutical company focused on the development and production of Active Pharmaceutical Ingredients (APIs) and chemical intermediates. Established in 1996, the company specializes in cardiovascular therapies, particularly angiotensin II receptor blockers (ARBs) and ACE inhibitors. Their core product portfolio includes high-demand APIs such as Valsartan, Irbesartan, and Enalapril, which are exported to global markets. The company operates large-scale, GMP-certified manufacturing facilities and provides contract development and manufacturing (CDMO) services. Zhejiang Changming is recognized for its expertise in complex chemical synthesis and its commitment to international quality standards.